SG153871A1 - Compositions and methods for treating neurological disorders - Google Patents
Compositions and methods for treating neurological disordersInfo
- Publication number
- SG153871A1 SG153871A1 SG200904395-1A SG2009043951A SG153871A1 SG 153871 A1 SG153871 A1 SG 153871A1 SG 2009043951 A SG2009043951 A SG 2009043951A SG 153871 A1 SG153871 A1 SG 153871A1
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- compositions
- neurodegenerative
- treating neurological
- neurological disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58299904P | 2004-06-25 | 2004-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG153871A1 true SG153871A1 (en) | 2009-07-29 |
Family
ID=35207559
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012095170A SG186686A1 (en) | 2004-06-25 | 2005-06-27 | Compositions and methods for treating neurological disorders |
SG200904395-1A SG153871A1 (en) | 2004-06-25 | 2005-06-27 | Compositions and methods for treating neurological disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012095170A SG186686A1 (en) | 2004-06-25 | 2005-06-27 | Compositions and methods for treating neurological disorders |
Country Status (18)
Country | Link |
---|---|
US (1) | US20060229233A1 (ru) |
EP (3) | EP1761276B1 (ru) |
JP (2) | JP5274011B2 (ru) |
KR (2) | KR101347105B1 (ru) |
CN (2) | CN101039691B (ru) |
AU (1) | AU2005259991B2 (ru) |
CA (1) | CA2571035A1 (ru) |
ES (1) | ES2432369T3 (ru) |
HK (1) | HK1101140A1 (ru) |
IL (1) | IL179933A (ru) |
MA (1) | MA28975B1 (ru) |
MX (1) | MXPA06015096A (ru) |
NO (1) | NO20070460L (ru) |
NZ (2) | NZ578727A (ru) |
RU (2) | RU2387453C2 (ru) |
SG (2) | SG186686A1 (ru) |
WO (1) | WO2006004749A2 (ru) |
ZA (1) | ZA200610661B (ru) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173140B2 (en) | 2003-10-22 | 2012-05-08 | Id Biomedical Corporation Of Quebec | Compositions and methods for activating innate and allergic immunity |
US8911751B2 (en) * | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
EP1957082B1 (en) * | 2005-12-02 | 2012-04-11 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
US7629135B2 (en) * | 2006-12-22 | 2009-12-08 | The Board Of Trustees Of The University Of Illinois | Toll-like receptor agonists and antagonists and methods of use thereof |
EP2185160B1 (en) | 2007-08-31 | 2019-02-13 | Neurimmune Holding AG | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
DE102007044487A1 (de) * | 2007-09-18 | 2009-04-02 | Universität Leipzig | Verwendung des umgekehrten Zelldifferenzierungsprogramms (OCDP) zur Behandlung degenerierter, im pathologischen Zustand befindlicher Organe |
MX2010003548A (es) * | 2007-10-01 | 2010-06-02 | Univ Johns Hopkins | Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida. |
US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
WO2009067699A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for an oxazaphosphorine drug regimen |
US10383887B2 (en) | 2008-02-20 | 2019-08-20 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
CA2722558A1 (en) * | 2008-04-25 | 2009-10-29 | Id Biomedical Corporation Of Quebec | Methods for preparing immunogenic compositions |
WO2009146301A1 (en) * | 2008-05-27 | 2009-12-03 | Yale University | TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE |
EP2405749B1 (en) * | 2009-08-20 | 2013-05-08 | Yeda Research and Development Co., Ltd. | Low frequency glatiramer acetate therapy |
KR101692097B1 (ko) | 2010-03-31 | 2017-01-02 | 톰슨 라이센싱 | 비디오 데이터의 트릭 재생 |
US9510758B2 (en) | 2010-10-27 | 2016-12-06 | The General Hospital Corporation | Apparatus, systems and methods for measuring blood pressure within at least one vessel |
TW201326399A (zh) | 2011-10-10 | 2013-07-01 | Teva Pharma | 用於預測對格拉替雷(glatiramer)醋酸鹽之臨床反應之單核苷酸多型性之判定 |
GB201300683D0 (en) * | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
US10493122B2 (en) | 2014-03-17 | 2019-12-03 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
JP2019519515A (ja) | 2016-05-20 | 2019-07-11 | シーダーズ—シナイ メディカル センター | アルツハイマー病およびアルツハイマー病に関係する疾病を処置または予防する方法 |
RU2629385C1 (ru) * | 2016-09-29 | 2017-08-29 | Владимир Федорович Корсун | Способ лечения рассеянного склероза |
GB201916185D0 (en) * | 2019-11-07 | 2019-12-25 | Randox Laboratories Ltd | Biomarker of drug-induced cellular toxicity and depression |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
US4606918A (en) * | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
US4770874A (en) * | 1983-08-22 | 1988-09-13 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
US4707543A (en) * | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
US5726292A (en) * | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
BR9506885A (pt) * | 1994-02-24 | 1997-08-19 | Micro Pak Inc | Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos |
US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
PL325604A1 (en) | 1995-09-18 | 1998-08-03 | Us Army Med Res Mat Command | Improved methods of obtaining non-covalently complexed and multvalent proteosomal subunitary vaccines |
US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
US6703015B1 (en) * | 1999-09-03 | 2004-03-09 | Ramot At Tel-Aviv University Ltd. | Filamentous bacteriophage displaying an β-amyloid epitope |
US6743427B1 (en) * | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
JP2000154148A (ja) * | 1998-11-20 | 2000-06-06 | Toray Ind Inc | インターフェロンβをアジュバントとするワクチン |
IL142948A0 (en) * | 1999-09-03 | 2002-04-21 | Univ Ramot | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
US20020052311A1 (en) * | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
AU780188B2 (en) * | 2000-01-20 | 2005-03-03 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
EP1255561B1 (en) * | 2000-02-15 | 2006-06-28 | ID Biomedical Corporation of Quebec | Proteosome influenza vaccine |
AU2001238469C1 (en) * | 2000-02-18 | 2006-08-24 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
KR20080017471A (ko) * | 2000-02-21 | 2008-02-26 | 파멕사 에이/에스 | 아밀로이드의 하향-조절을 위한 신규한 방법 |
WO2002072012A2 (en) | 2001-03-09 | 2002-09-19 | Id Biomedical Corporation Of Quebec | A novel proteosome-liposaccharide vaccine adjuvant |
US7255867B2 (en) * | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
JP2007505836A (ja) * | 2003-09-15 | 2007-03-15 | アイディー バイオメディカル コーポレイション オブ ケベック | 麻疹サブユニットワクチン |
US8173140B2 (en) * | 2003-10-22 | 2012-05-08 | Id Biomedical Corporation Of Quebec | Compositions and methods for activating innate and allergic immunity |
JP2007509981A (ja) * | 2003-10-31 | 2007-04-19 | テバ ファーマシューティカル インダストリーズ リミティド | 薬物デリバリー用ナノ粒子 |
RU2007103343A (ru) * | 2004-06-30 | 2008-08-10 | АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК (CA) | Вакцинная композиция и способы лечения коронавирусной инфекции |
EP1797109B1 (en) * | 2004-09-09 | 2016-02-24 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
-
2005
- 2005-06-27 CN CN2005800211961A patent/CN101039691B/zh active Active
- 2005-06-27 KR KR1020127024992A patent/KR101347105B1/ko active IP Right Grant
- 2005-06-27 EP EP05787543.7A patent/EP1761276B1/en active Active
- 2005-06-27 NZ NZ578727A patent/NZ578727A/en unknown
- 2005-06-27 MX MXPA06015096A patent/MXPA06015096A/es active IP Right Grant
- 2005-06-27 ES ES05787543T patent/ES2432369T3/es active Active
- 2005-06-27 SG SG2012095170A patent/SG186686A1/en unknown
- 2005-06-27 EP EP10010617A patent/EP2332569A3/en not_active Withdrawn
- 2005-06-27 WO PCT/US2005/022922 patent/WO2006004749A2/en active Application Filing
- 2005-06-27 SG SG200904395-1A patent/SG153871A1/en unknown
- 2005-06-27 RU RU2007102698/14A patent/RU2387453C2/ru active
- 2005-06-27 CN CN2012104014288A patent/CN103143011A/zh active Pending
- 2005-06-27 KR KR1020077001913A patent/KR101347562B1/ko active IP Right Grant
- 2005-06-27 NZ NZ552075A patent/NZ552075A/en unknown
- 2005-06-27 CA CA002571035A patent/CA2571035A1/en not_active Abandoned
- 2005-06-27 EP EP10010618A patent/EP2332570A1/en not_active Withdrawn
- 2005-06-27 JP JP2007518369A patent/JP5274011B2/ja active Active
- 2005-06-27 AU AU2005259991A patent/AU2005259991B2/en active Active
- 2005-06-27 US US11/167,489 patent/US20060229233A1/en not_active Abandoned
-
2006
- 2006-12-10 IL IL179933A patent/IL179933A/en active IP Right Grant
- 2006-12-18 ZA ZA200610661A patent/ZA200610661B/xx unknown
- 2006-12-29 MA MA29599A patent/MA28975B1/fr unknown
-
2007
- 2007-01-24 NO NO20070460A patent/NO20070460L/no not_active Application Discontinuation
- 2007-08-27 HK HK07109272.3A patent/HK1101140A1/xx unknown
-
2010
- 2010-02-01 RU RU2010103240/15A patent/RU2010103240A/ru not_active Application Discontinuation
-
2011
- 2011-09-28 JP JP2011211735A patent/JP2012041351A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG153871A1 (en) | Compositions and methods for treating neurological disorders | |
WO2004110389A3 (en) | Sigma ligands for neuronal regeneration and functional recovery | |
DE602005025897D1 (de) | Verfahren und zusammensetzungen in verbindung mit morbus alzheimer | |
IL220065A0 (en) | Methods of preventing, treating and diagnosing disorders of protein aggregation | |
WO2008002933A3 (en) | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof | |
BRPI0417959A (pt) | anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável | |
WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
WO2008157791A3 (en) | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones | |
MX2020010907A (es) | Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central. | |
DE60333857D1 (de) | Oxytocin zur Behandlung von Autismus und Asperger-Syndrom | |
WO2007035722A8 (en) | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration | |
WO1995018616A3 (en) | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor | |
ATE504310T1 (de) | Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c | |
WO2005003103A3 (en) | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases | |
WO2007053580A3 (en) | Sigma ligands for neuronal regeneration and functional recovery | |
WO1999048489A3 (en) | Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders | |
HK1063601A1 (en) | Compositions and methods for treating hyperimmune response in the eye | |
WO2004028468A3 (en) | Methods and compositions for treatment of neurological disorder | |
WO2007106862A3 (en) | The use of statins to stimulate neurogenesis | |
WO2006138316A3 (en) | Methods for delivering molecules to the central nervous system | |
AR043252A1 (es) | Formulaciones de glucocorticoesteroides para tratar angiogenia ocular patologica | |
ATE548048T1 (de) | Oncomodulin zur behandlung von neurologishen erkrankungen | |
MX2022008953A (es) | Factores de transcripcion de proteina de dedos de zinc para reprimir la expresion de tau. | |
BRPI0512551A (pt) | composições e métodos para tratar distúrbios neurológicos | |
WO2002076437A3 (en) | Methods for treating neurodegenerative diseases including alzheimer's |